Cytodyn Inc (CYDY)

[The Blue Baron]

Below is a positive story about Leronlimab and reveals a potential benefit in regards to antibodies.

“We don’t know for sure if the Leronlimab was what turned her around. I believe it probably did, the improvement she had after she got the drug was dramatic,” Dr. Yang said.

The drug is now being studied in a placebo-controlled clinical trial and UCLA is one of the trial sites.

Dr. Yang said not all of his patients responded to Leronlimab as well as Mottet and the trial results will offer more insight into its efficacy. But when he last read her antibody count, it was over 100,000.

“She’s about 10 times higher than the typical person’s antibodies,” Dr. Yang said.

Dr. Yang recently published a study on antibodies in COVID-19 patients in the New England Journal of Medicine, and found that antibodies fall sharply in the first three months after battling the virus, especially in mild cases of COVID-19. But Mottet was a rare exception.

spectrumnews1.com/...